Ex-US revenue rose sharply by 21% YoY to Rs. 22,404 million ($254 million); Operational PAT grew 50.3% YoY to Rs. 5,181 million
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Dilip Shanghvi to continue as the Executive Chairman of the Board
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Subscribe To Our Newsletter & Stay Updated
